Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc reduced its stake in Teva Pharmaceutical Industries Ltd. by 45.8%, now holding 235,721 shares valued at approximately $3.62 million.
• Other institutional investors significantly increased their holdings in Teva, with Harel Insurance augmenting its stake by a staggering 197,885.2%.
• Teva reported earnings of $0.66 per share for the last quarter, surpassing analysts' expectations, with revenues totaling $4.18 billion, slightly below consensus estimates.

TD Asset Management Inc lowered its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 45.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,721 shares of the company's stock after selling 198,833 shares during the quarter. TD Asset Management Inc's holdings in Teva Pharmaceutical Industries were worth $3,623,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of TEVA. Bfsg LLC boosted its position in Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after buying an additional 790 shares during the period. Townsquare Capital LLC raised its stake in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after acquiring an additional 812 shares in the last quarter. Quadrant Capital Group LLC grew its position in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the last quarter. Blair William & Co. IL grew its position in Teva Pharmaceutical Industries by 9.4% during the 4th quarter. Blair William & Co. IL now owns 11,232 shares of the company's stock worth $248,000 after purchasing an additional 963 shares during the last quarter. Finally, Yousif Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after acquiring an additional 1,033 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 0.2%

Teva Pharmaceutical Industries stock traded up $0.03 during trading on Tuesday, reaching $15.72. The stock had a trading volume of 12,366,716 shares, compared to its average volume of 12,271,082. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The business has a 50 day moving average price of $16.86 and a 200 day moving average price of $16.56. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The stock has a market cap of $18.03 billion, a PE ratio of -98.25, a P/E/G ratio of 0.91 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the previous year, the firm earned $0.61 EPS. The company's revenue was up .3% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TEVA. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.71.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock worth $996,958 in the last ninety days. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.